1. Home
  2. BAFN vs CLSD Comparison

BAFN vs CLSD Comparison

Compare BAFN & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BAFN
  • CLSD
  • Stock Information
  • Founded
  • BAFN 1999
  • CLSD 2011
  • Country
  • BAFN United States
  • CLSD United States
  • Employees
  • BAFN N/A
  • CLSD N/A
  • Industry
  • BAFN Savings Institutions
  • CLSD Biotechnology: Pharmaceutical Preparations
  • Sector
  • BAFN Finance
  • CLSD Health Care
  • Exchange
  • BAFN Nasdaq
  • CLSD Nasdaq
  • Market Cap
  • BAFN 65.2M
  • CLSD 59.1M
  • IPO Year
  • BAFN N/A
  • CLSD 2016
  • Fundamental
  • Price
  • BAFN $14.52
  • CLSD $0.80
  • Analyst Decision
  • BAFN
  • CLSD Strong Buy
  • Analyst Count
  • BAFN 0
  • CLSD 4
  • Target Price
  • BAFN N/A
  • CLSD $4.75
  • AVG Volume (30 Days)
  • BAFN 14.1K
  • CLSD 402.9K
  • Earning Date
  • BAFN 07-29-2025
  • CLSD 08-11-2025
  • Dividend Yield
  • BAFN 2.20%
  • CLSD N/A
  • EPS Growth
  • BAFN 116.26
  • CLSD N/A
  • EPS
  • BAFN 2.37
  • CLSD N/A
  • Revenue
  • BAFN $80,167,000.00
  • CLSD $3,764,000.00
  • Revenue This Year
  • BAFN N/A
  • CLSD $60.52
  • Revenue Next Year
  • BAFN N/A
  • CLSD $88.28
  • P/E Ratio
  • BAFN $6.12
  • CLSD N/A
  • Revenue Growth
  • BAFN 2.60
  • CLSD N/A
  • 52 Week Low
  • BAFN $11.66
  • CLSD $0.70
  • 52 Week High
  • BAFN $19.75
  • CLSD $1.65
  • Technical
  • Relative Strength Index (RSI)
  • BAFN 48.06
  • CLSD 50.60
  • Support Level
  • BAFN $13.85
  • CLSD $0.79
  • Resistance Level
  • BAFN $14.95
  • CLSD $0.82
  • Average True Range (ATR)
  • BAFN 0.70
  • CLSD 0.04
  • MACD
  • BAFN 0.02
  • CLSD 0.00
  • Stochastic Oscillator
  • BAFN 65.35
  • CLSD 52.50

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

About CLSD Clearside Biomedical Inc.

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Share on Social Networks: